Rain Therapeutics Inc.

NASDAQ:RAIN

1.21 (USD) • At close January 25, 2024
Bedrijfsnaam Rain Therapeutics Inc.
Symbool RAIN
Munteenheid USD
Prijs 1.21
Beurswaarde 44,014,599
Dividendpercentage 0%
52-weken bereik 0.82 - 11.32
Industrie Biotechnology
Sector Healthcare
CEO Mr. Avanish Vellanki M.B.A.
Website https://www.rainthera.com

An error occurred while fetching data.

Over Rain Therapeutics Inc.

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is

Vergelijkbare Aandelen

Bionomics Limited logo

Bionomics Limited

BNOX

0.272 USD

Novo Integrated Sciences, Inc. logo

Novo Integrated Sciences, Inc.

NVOS

0.272 USD

InflaRx N.V. logo

InflaRx N.V.

IFRX

1.55 USD

DiaMedica Therapeutics Inc. logo

DiaMedica Therapeutics Inc.

DMAC

4.29 USD

SCYNEXIS, Inc. logo

SCYNEXIS, Inc.

SCYX

1.51 USD

Orgenesis Inc. logo

Orgenesis Inc.

ORGS

3.238 USD

Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc.

AKBA

1.33 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)